Corpus Intelligence IC Memo — MENIFEE VALLEY MEDICAL CENTER 2026-04-26 15:58 UTC
IC Memo — MENIFEE VALLEY MEDICAL CENTER
Investment Committee Memorandum | CA | 84 beds | Grade D | EBITDA uplift $3.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MENIFEE VALLEY MEDICAL CENTER

CCN 050684 | RIVERSIDE, CA | 84 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

MENIFEE VALLEY MEDICAL CENTER is a 84-bed safety-net/medicaid heavy in RIVERSIDE, CA with $46.7M in net patient revenue and a -3.4% operating margin. The hospital serves a payer mix of 10.2% Medicare, 46.9% Medicaid, and 42.9% commercial.

Thesis: Turnaround. Our ML models identify $3.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -3.4% to 3.9% (+736bps).

Net Revenue HCRIS$46.7M
Current EBITDA COMPUTED$-1.6M
Operating Margin COMPUTED-3.4%
Occupancy HCRIS47.3%
Revenue / Bed COMPUTED$556K
Net-to-Gross HCRIS23.5%
Distress Probability ML58.8%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
158
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -3.4% places it above the state median. Among 158 size-comparable peers (42-168 beds), the median margin is -4.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (42-168), prioritizing same-state peers. 158 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MENIFEE VALLEY MEDICAL CENTER (Target)CA84$46.7M-3.4%
CHILDRENS HOSP & RES CNTR OAKLCA155$687.9M-7.1%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - ANTIOCHCA144$445.4M8.1%
KFH - VACAVILLECA144$415.3M7.1%
SCRIPPS GREEN HOSPITALCA150$403.2M14.2%
EDEN MEDICAL CENTERCA126$389.8M2.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$980K+210bp18mo
Cost to Collect4.5%2.5%$934K+200bp12mo
Denial Rate Reduction12.0%6.5%$924K+198bp12mo
A/R Days Reduction5200.0%3800.0%$568K+122bp9mo
Clean Claim Rate88.0%96.0%$30K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$980K
Cost to Collect
$934K
Denial Rate Reduction
$924K
A/R Days Reduction
$568K
Clean Claim Rate
$30K
Total EBITDA Uplift$3.4M
Current EBITDA$-1.6M
+ RCM Uplift+$3.4M
Pro Forma EBITDA$1.8M
Current Margin-3.4%
Pro Forma Margin3.9%
WC Released (1x)$1.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.5M$23.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.5M$25.4M0.00x-100.0%
Bull Case9.0x11.0x$-2.2M$36.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.2M$38.6M0.00x-100.0%
Bear Case11.0x10.0x$-2.7M$7.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.7M$7.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (46.9%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 58.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 158 hospitals with 42-168 beds
  • Same-state prioritization (n=159)
  • Comp margins: P25=-21.6% / P50=-4.7% / P75=3.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.